Dr. Jay Bhattacharya outlines key initiatives at the NIH, including a $50 million Autism Data Science Initiative exploring Leucovorin as a targeted therapy and reevaluating prenatal Tylenol use due to potential autism risks. He addresses broader challenges like rising preterm birth rates and the replication crisis, attributing them to risk-averse funding cultures and misaligned incentives. To counter this, the NIH is reforming grant processes, empowering early-career scientists, and promoting academic freedom by removing publication barriers. Rebuilding public trust requires transparent communication, humility, and acknowledging scientific uncertainty. Strategic priorities include tackling chronic diseases, leveraging AI for drug discovery and diagnostics, and repurposing existing treatments like Zostavax for Alzheimer’s prevention. While AI enhances efficiency in research and healthcare, it remains a tool that augments—rather than replaces—human judgment. The conversation concludes with a call to support high-risk, transformative science, emphasizing that breakthroughs often emerge from persistence and diverse, long-term investment.